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Tweetable abstract: Reduced KCO in discharged patients with COVID-19 suggests 




To the Editor, 
 
We read with much interest the recent findings published in the European 
Respiratory Journal of reduced gas transfer in patients following COVID-19. Drs Mo 
et al (1) investigated conventional pulmonary function in survivors of mild, moderate 
and severe COVID-19 approximately 20-30 days after onset of symptoms. While 
patients had relatively normal spirometry, DLCO was reduced in 50% and DLCO/VA 
(or KCO, to avoid misinterpretation) reduced in 25%. These findings are welcome as 
they provide significant insight into the long-term lung function impairment 
associated with COVID-19.  
In response, Dr Nusair (2) contributed the interpretation that “low DLCO is caused 
mainly by reduced alveolar volume, and not residual interstitial abnormalities or 
pulmonary vascular abnormalities caused by COVID-19” i.e. normal capillary-
alveolar units. However, we believe that this interpretation does not consider the 
complex relationship between VA, DLCO and KCO, and may prematurely rule out 
the presence of abnormal gas exchange. To demonstrate our point, Figure 1 
illustrates the expected effect of a reduction in VA on DLCO and KCO due to either 
suboptimal alveolar expansion or loss of alveolar units (with normal expansion in 
communicating alveoli) (3). Firstly, it is evident that in the “severe pneumonia” 
patients in the study by Mo et al the impairment in DLCO (1) (represented by the 
star) is considerably greater than expected if a reduction in VA was the sole 
abnormality, regardless of the mechanism for the reduced VA. Secondly, a reduction 
in VA due to either aforementioned mechanism would be is associated with an 
increase in KCO, which is opposite to the reduced KCO in many of the discharged 
patients with severe COVID-19 (3). This reduction in KCO suggests that loss of 
alveolar units is not sufficient to cause the observed impairment in DLCO.   
   
Thus, while the DLCO findings of Mo et al (1) are partially explained by reduced VA, 
the reduction in KCO measured at that reduced VA also implicates abnormal gas 
exchange. Whether this is due to disruption of the alveolar-capillary barrier or 
abnormal pulmonary blood volume cannot be determined based on their data. Lung 
fibrosis associated with acute respiratory distress syndrome in COVID-19 patients 
(4), would likely damage alveolar-capillary units, leading to loss of alveolar units and 
impaired gas exchange. The result would be a reduction in both VA and KCO (for the 
reduced VA). There is increasing suggestion of altered pulmonary haemodynamics 
in COVID-19 patients (5), including vascular pruning and reduced pulmonary blood 
volume measured via high resolution CT (6). Use of more specific measures of the 
alveolar-capillary membrane, such as combined DLCO and DLNO measurements or 
advanced imaging techniques, are likely required to determine whether interstitial 
abnormalities or pulmonary vascular abnormalities contribute to reduced DLCO in 




Figure 1: The relationship between alveolar volume (VA) and, [A] diffusing capacity 
for carbon monoxide (DLCO) and [B] rate constant for CO uptake (KCO), are plotted 
as a percentage of the value at total lung capacity (TLC). The relationships are 
shown for two situations that result in reduced VA; i) suboptimal alveolar expansion 
(DLCO and KCO measured at volumes below maximum TLC, solid line), ii) loss of 
alveolar units (e.g. theoretical removal of lobules or lobes with remaining lung 
expanded to its normal TLC, dashed line). The star (   ) represents the group mean 
data of the ‘severe pneumonia’ from Mo et al (1). Mean VA was calculated as mean 
percent predicted DLCO/ mean percent predicted KCO. The relationship between 
VA, DLCO and KCO was calculated using the equations as described in (3) :  for 
suboptimal alveolar expansion, KCO= 0.43 + (0.57/VA); for loss of alveolar lung 
units, change in KCO = 0.4x + 2.1 where x = the proportion of volume diverted to the 
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